---
title: "Cerus 10-K: Revenue $233.8M, product growth drives results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277525712.md"
description: "Cerus reported a total revenue of $233.8 million for the year, marking a 16% increase from 2024, driven by higher product sales. Product revenue reached $206.1 million, a 14% year-over-year increase. The company has combined cash and short-term investments of $82.9 million. Key highlights include U.S. approvals for new systems, ongoing clinical trials, and government contracts supporting product rollout and commercialization efforts."
datetime: "2026-03-02T22:05:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277525712.md)
  - [en](https://longbridge.com/en/news/277525712.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277525712.md)
---

# Cerus 10-K: Revenue $233.8M, product growth drives results

Cerus reported total revenue of $233.8 million for the year, driven by higher product sales, and disclosed combined cash and short-term investments of $82.9 million. The filing highlights product revenue growth and operational progress across commercialization and clinical programs for its blood safety platforms. Cerus noted ongoing clinical and regulatory activities that support future product rollout and market adoption.

**Financial Highlights**

-   **Total revenue:** $233.8 million (16% increase versus 2024)
-   **Product revenue:** $206.1 million (14% year-over-year increase)
-   **Gross Profit:** $112.3 million (as reported in summaries)
-   **Cash & short-term investments:** $82.9 million combined ($19.961M cash, $62.918M short-term investments)
-   **Working capital:** $73.2 million

**Business Highlights**

-   **Revenue mix and channel dynamics:** Growth was primarily driven by higher product sales; Institute for Flow Cytometry (IFC) sales shifted from direct hospital sales toward increased kit sales to blood centers, accelerating demand for kits.
-   **Commercial momentum:** U.S. approvals for platelet, plasma and cryoprecipitation systems support continued market adoption and commercialization of IFC products.
-   **R&D and regulatory progress:** Continued Phase 3 trials (RedeS, ReCePI) and MDR resubmission for the red blood cell system, with additional clinical data expected to inform further regulatory steps.
-   **Government contracts and development support:** BARDA and DoD contracts provided development funding and reimbursement for clinical and scale-up activities, aiding product rollout and commercialization efforts.

Original SEC Filing: CERUS CORP \[ CERS \] - 10-K - Mar. 02, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [CERS.US](https://longbridge.com/en/quote/CERS.US.md)

## Related News & Research

- [KALA BIO 10-K: Operating loss $39.16M; Net loss $26.98M](https://longbridge.com/en/news/282893053.md)
- [Novo Nordisk's stock rallies after drugmaker reveals deal with OpenAI](https://longbridge.com/en/news/282698267.md)
- [Emergent BioSolutions Secures $150 Million Term Loan Plus $75 Million Delayed Draw From OrbiMed](https://longbridge.com/en/news/283125024.md)
- [BUZZ-Cancer biotech Adlai Nortye jumps after $150 mln equity financing](https://longbridge.com/en/news/282996483.md)
- [OpenAI launches AI model GPT-Rosalind for life sciences research](https://longbridge.com/en/news/283043237.md)